Chemomab Therapeutics annual return on equity
2017
2018
2019
2020
2021
2022
2023
2024
2025
Chemomab Therapeutics Return on Equity (ROE) Growth & History (CMMB)
Chemomab Therapeutics's return on equity was −69.54% for fiscal 2025.
View full Chemomab Therapeutics company overviewChemomab Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −69.54% | +21.80 pp |
| 2024 | 2024-12-31 | −91.34% | −0.32 pp |
| 2023 | 2023-12-31 | −91.02% | −34.42 pp |
| 2022 | 2022-12-31 | −56.60% | −22.07 pp |
| 2021 | 2021-12-31 | −34.53% | +16.82 pp |
| 2020 | 2020-12-31 | −51.36% | +193.25 pp |
| 2019 | 2019-12-31 | −244.60% | +55.48 pp |
| 2018 | 2018-12-31 | −300.09% | +429.80 pp |
| 2017 | 2017-12-31 | −729.88% | — |
Chemomab Therapeutics quarterly return on equity
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −22.34% | −1.87 pp |
| Q1 2026 | 2026-03-31 | −15.40% | +12.37 pp |
| Q4 2025 | 2025-12-31 | −15.90% | — |
| Q3 2025 | 2025-09-30 | −16.65% | — |
| Q2 2025 | 2025-06-30 | −20.48% | +6.44 pp |
| Q1 2025 | 2025-03-31 | −27.77% | — |
| Q2 2024 | 2024-06-30 | −26.91% | +5.00 pp |
| Q2 2023 | 2023-06-30 | −31.92% | −20.56 pp |
| Q1 2023 | 2023-03-31 | −27.28% | −18.68 pp |
| Q4 2022 | 2022-12-31 | −20.46% | −12.53 pp |
| Q3 2022 | 2022-09-30 | −16.75% | −12.31 pp |
| Q2 2022 | 2022-06-30 | −11.35% | −6.85 pp |
| Q1 2022 | 2022-03-31 | −8.60% | −3.43 pp |
| Q4 2021 | 2021-12-31 | −7.93% | +9.06 pp |
| Q3 2021 | 2021-09-30 | −4.44% | +5.37 pp |
| Q2 2021 | 2021-06-30 | −4.50% | +4.70 pp |
| Q1 2021 | 2021-03-31 | −5.17% | +9.51 pp |
| Q4 2020 | 2020-12-31 | −17.00% | +33.54 pp |
| Q3 2020 | 2020-09-30 | −9.81% | — |
| Q2 2020 | 2020-06-30 | −9.19% | — |
| Q1 2020 | 2020-03-31 | −14.68% | — |
| Q4 2019 | 2019-12-31 | −50.54% | — |
Chemomab Therapeutics return on equity trends
Over the last five fiscal years, Chemomab Therapeutics's return on equity decreased from −51.36% to −69.54%, a change of −18.18 percentage points. The latest reported quarter, Q2 2026, shows −22.34%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Chemomab Therapeutics source filings ↗